Antidepressant-Induced Sexual Dysfunction During Treatment With Moclobemide, Paroxetine, Sertraline, and Venlafaxine
J Clin Psychiatry 2000;61:276-281
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Recent reports suggest that adverse
effects on sexual function occur in up to 50% of patients who are
treated with selective serotonin reuptake inhibitor (SSRI)
antidepressants. Previously cited low rates were more likely a
function of underreporting than underoccurrence. There is less
evidence about rates of dysfunction with serotonin-norepinephrine
reuptake inhibitor (SNRI) and reversible inhibitor of monoamine
oxidase A (RIMA) antidepressants. The purpose of this report is
to evaluate disturbances in sexual drive/desire and
arousal/orgasm in 107 patients who met criteria for major
depressive disorder and received treatment with either
moclobemide, paroxetine, sertraline, or venlafaxine.
Method: All consenting eligible patients who met
DSM-IV criteria for major depressive disorder completed the
Sexual Functioning Questionnaire, version 1 (SFQ) and were
assessed using the 17-item Hamilton Rating Scale for Depression
(HAM-D) prior to and after 8 or 14 weeks of antidepressant
therapy. Analyses were carried out to examine the effect of
gender, drug type, pretreatment level of sexual dysfunction, and
drug response on reported sexual dysfunction.
Results: Compared with women, men experienced a
significantly greater level of drug-related impairment in
drive/desire (p < .05), whereas there were no statistically
significant differences in levels of arousal/orgasm impairment
between men and women. The reported impairment in drive/desire
items for men ranged from 38% to 50% and from 26% to 32% for
women. No differences were found across the 4 antidepressants in
men, whereas in women, rates of dysfunction were generally higher
with sertraline and paroxetine, but only significantly so in
comparison with moclobemide on some measures (p < .03). Rates
of sexual dysfunction with venlafaxine tended to fall between
those of SSRIs and the RIMA agent. An unexpected relationship was
found between favorable drug response and a decreased level of
drug-induced sexual dysfunction.
Conclusion: Antidepressant-induced sexual
dysfunction occurs in approximately 30% to 70% of patients who
are treated with sertraline or paroxetine. Lower rates are
reported with moclobemide and venlafaxine. Clinicians should
evaluate the various aspects of sexual dysfunction before and
during antidepressant therapy.